Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 41 clinical trials
RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced

cancer of the esophagus
cancer
medi4736
neutrophil count
oophorectomy
  • 0 views
  • 23 Jan, 2021
  • 1 location
Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design

A Phase II study of immunotherapy with durvalumab (MEDI4736) and tremelimumab in combination with either Y-90 SIRT or TACE for intermediate stage HCC with pick-the-winner design

  • 0 views
  • 24 Feb, 2021
  • 2 locations
Testing the Combination of the Anti-cancer Drugs Copanlisib Olaparib and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

This phase Ib trial studies side effects and best dose of copanlisib and olaparib when given together with durvalumab, and how well they work in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). Copanlisib may stop …

metastasis
international normalized ratio
PIK3CA
cancer
neutrophil count
  • 3 views
  • 12 Jun, 2021
  • 4 locations
Window of Opportunity Trial of Durvalumab (MEDI4736) or Durvalumab/Tremelimumab as Neoadjuvant Chemotherapy to Identify Immune Dynamics in Surgically Resectable Head and Neck Cancer Patients.

This is a phase II randomized, open label study of durvalumab with/ without tremelimumab as neoadjuvant therapy and durvalumab maintenance after SoC RTx with/without cisplatin as post-surgical adjuvant therapy in treatment nave participants with newly diagnosed resectable LA HNSCC. The study will be conducted in conformance with Good Clinical Practices …

  • 0 views
  • 02 May, 2021
  • 1 location
Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers

This is a phase II study that will assess if Durvalumab (MEDI4736) used as induction chemo-immunotherapy followed by concurrent chemo-immuno-radiotherapy and consolidation immunotherapy may

immunosuppressive
cancer
carboplatin
  • 0 views
  • 24 Sep, 2021
  • 7 locations
Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC

participate in this phase II open label study of concurrent, split course chemoradiation followed by Durvalumab (MEDI4736).

  • 0 views
  • 20 Mar, 2021
  • 1 location
Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

This is a non-randomized, open-label, Phase IbI study to assess the safety and efficacy of oral decitabine (ASTX727) and durvalumab (MEDI4736) combination therapy in the treatment of patients

metastasis
head and neck carcinoma
squamous cell carcinoma
metastatic squamous cell carcinoma
squamous cell carcinoma of head and neck
  • 15 views
  • 27 Jan, 2021
Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas

this study is to assess the tolerability and efficacy of combining Durvalumab (MEDI4736), Tremelimumab and SBRT in controlling cancer progression. SBRT will be administered to patients while they are

metastasis
measurable disease
squamous cell carcinoma
locoregional recurrence
cancer
  • 21 views
  • 02 Jun, 2021
  • 6 locations
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study)

This phase II trial studies the benefit of adding an immunotherapy drug called MEDI4736 (durvalumab) to standard chemotherapy and radiation therapy in treating bladder cancer which has spread to

bladder tumor
metastasis
transurethral resection
gemcitabine
cancer
  • 0 views
  • 23 Sep, 2021
  • 158 locations
Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian Triple Negative Breast Lung Prostate and Colorectal Cancers

Background MEDI4736 is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of

metastasis
cancer of the ovary
platinum-based chemotherapy
cancer chemotherapy
cancer
  • 31 views
  • 26 Sep, 2021
  • 1 location